{
    "patient": {
        "Name": "Lisa Robinson",
        "DateOfBirth": "1970-04-29",
        "Sex": "Male",
        "Diagnosis": "Hodgkin lymphoma",
        "BodyPart": "Lymphoma",
        "Physician": "Dr. Lisa Garrett",
        "TreatingInstitution": "Williams, Sherman and Carr"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Lymphoma",
            "CollectedDate": "2023-07-30",
            "ReceivedDate": "2023-08-01",
            "TumorPercentage": "15%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-08-05",
            "ReceivedDate": "2023-08-05"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "FOXL2",
                "DNA Alteration": "c.402C>G",
                "GeneMutation": "p.C134W Spliceregionvariant-LOF",
                "VariantAlleleFraction": "5.64%"
            },
            {
                "Gene": "AKT1",
                "DNA Alteration": "c.49G>A",
                "GeneMutation": "p.E17K Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "7.82%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "CSF3R",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G751A Nonsense-GOF",
                "VariantAlleleFraction": "23.83%"
            },
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.94G>A",
                "GeneMutation": "p.D32G Stopgain-LOF",
                "VariantAlleleFraction": "4.13%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "MUTYH",
            "SRSF2",
            "EZH2",
            "DDR2"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "4 m/Mb",
            "Tmbpercentile": "45%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Stable"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "MYOD1",
                "DNA Alteration": "c.365T>G",
                "GeneMutation": "p.L122R Spliceregionvariant-LOF",
                "VariantAlleleFraction": "7.83%"
            },
            {
                "Gene": "PDGFRB",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.T681I Spliceregionvariant-GOF",
                "VariantAlleleFraction": "16.05%"
            },
            {
                "Gene": "ARID2",
                "DNA Alteration": " c.798G>A",
                "GeneMutation": " p.W266* Spliceregionvariant-LOF",
                "VariantAlleleFraction": "6.51%"
            },
            {
                "Gene": "MSH2",
                "DNA Alteration": "c.1906G>C",
                "GeneMutation": "p.A636P Nonsense-GOF",
                "VariantAlleleFraction": "5.65%"
            },
            {
                "Gene": "TP53",
                "DNA Alteration": "c.523C>T",
                "GeneMutation": "p.R213L Frameshift-LOF",
                "VariantAlleleFraction": "9.0%"
            },
            {
                "Gene": "KIT",
                "DNA Alteration": "c.1676T>A",
                "GeneMutation": "p.Y846C Nonsense-GOF",
                "VariantAlleleFraction": "5.54%"
            },
            {
                "Gene": "NRAS",
                "DNA Alteration": "c.181_182delinsTT",
                "GeneMutation": "p.G13X Frameshift-LOF",
                "VariantAlleleFraction": "5.36%"
            },
            {
                "Gene": "TOP2A",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G1386D Nonsense-LOF",
                "VariantAlleleFraction": "4.57%"
            },
            {
                "Gene": "FGFR2",
                "DNA Alteration": "c.758C>G",
                "GeneMutation": "p.N549H Stopgain-LOF",
                "VariantAlleleFraction": "1.96%"
            },
            {
                "Gene": "NCSTN",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A572G Spliceregionvariant-LOF",
                "VariantAlleleFraction": "7.42%"
            },
            {
                "Gene": "PIK3CA",
                "DNA Alteration": "c.1633G>A",
                "GeneMutation": "p.H1047Q Spliceregionvariant-LOF",
                "VariantAlleleFraction": "8.87%"
            },
            {
                "Gene": "STAT5B",
                "DNA Alteration": "c.1924A>C",
                "GeneMutation": "p.N713_A714insKGKGGG Stopgain-LOF",
                "VariantAlleleFraction": "9.42%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "FOXL2",
        "PDGFRA"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "FOXL2",
                "DNA Alteration": "c.402C>G",
                "GeneMutation": "p.C134W Spliceregionvariant-LOF",
                "description": "TP53 encodes a protein that is a transcription factor that regulates the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair. TP53 is a tumor suppressor gene that is mutated in many cancers. Mutations in TP53 are associated with cancer progression.",
                "VariantAlleleFraction": "5.64%"
            },
            {
                "Gene": "AKT1",
                "DNA Alteration": "c.49G>A",
                "GeneMutation": "p.E17K Missensevariant(exon2)-GOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "7.82%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "CSF3R",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G751A Nonsense-GOF",
                "description": "BCL11B encodes a C2H2-type zinc finger protein that functions as a transcriptional repressor and plays a role in T-cell development and survival. Loss of function mutations, copy number loss, and fusions resulting in the underexpression of BCL11B are associated with cancer progression.",
                "VariantAlleleFraction": "23.83%"
            },
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.94G>A",
                "GeneMutation": "p.D32G Stopgain-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "4.13%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-07-29"
    },
    "other": {
        "ReportId": "8439",
        "ReportDate": "2023-07-30",
        "SignedBy": "Lisa Garrett",
        "Supervisor": "Dr. Michael Scott"
    }
}